Anxiety and depression related to elevated dopamine in a patient with multiple mediastinal paragangliomas

General Hospital Psychiatry

Volumn 36, Issue 4, 2014, Pages 449.e7-449.e8

  Bonomaully, Matt ^a   Khong, Teck ^b   Fotriadou, Maria ^c   Tully, John ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anxiety; Catecholamines; Depression; Neuroendocrinology; Paragangliomas

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; DOPAMINE; NEUROLEPTIC AGENT; NORADRENALIN; PARACETAMOL;

ADRENALECTOMY; ADULT; AMENORRHEA; ANEMIA; ANXIETY DISORDER; ARTICLE; AUDITORY HALLUCINATION; CAROTID BODY TUMOR; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DELUSION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOPAMINE URINE LEVEL; DRUG OVERDOSE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC SCREENING; HEADACHE; HUMAN; MEDIASTINAL PARAGANGLIOMA; MEDIASTINUM TUMOR; MENTAL HEALTH SERVICE; PARAGANGLIOMA; PARANOID SCHIZOPHRENIA; PHEOCHROMOCYTOMA; POSTOPERATIVE PERIOD; SDHD; TREATMENT OUTCOME; ANXIETY; COMPLICATION; MEDIASTINAL NEOPLASMS; PATHOLOGY; SCHIZOPHRENIA, PARANOID; SECRETION (PROCESS); YOUNG ADULT;

ADULT; ANXIETY; DEPRESSION; DOPAMINE; FEMALE; HUMANS; MEDIASTINAL NEOPLASMS; PARAGANGLIOMA; SCHIZOPHRENIA, PARANOID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902823527     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2014.03.003     Document Type: Article

References (21)

1. Fruhmann J., Geigl J.B., Konstantiniuk P., Cohnert T.U. Paraganglioma of the carotid body: treatment strategy and SDH gene mutations. Eur J Vasc Endovasc Surg 2013, 45:431-436.
2. Raygada M., Pasini B., Stratakis C.A. Hereditary paragangliomas. Medical genetics in the clinical practice of ORL 2011, 99-106. Karger, Basel. R. Alford, V. Sutton (Eds.).
3. Martin T., Irving R., Maher E. The genetics of paragangliomas: a review. Clin Otolargnol 2007, 32:7-11.
4. Erickson D., Yogish C., Kudva M.J., et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001, 86:5210-5216.
5. Neumann H.P., Pawlu C., Pe{ogonek}czkowska M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. J Am Med Assoc 2004, 292:943-951.
6. Metzer S., Lucy D. Hypermetabolic disorders presenting as headache with anxiety and depression. Headache 1987, 27:571-572.
7. Medvei V.C., Cattell W.R. Mental symptoms presenting in phaeochromocytoma: a case report and review. J Roy Soc Med 1988, 81:550.
8. Benabarre A., Bosch X., Plana M.T., et al. Relapsing paranoid psychosis as the first manifestation of pheochromocytoma. J Clin Psychiatry 2005, 66:949-950.
9. Plouin P.F., Gimenez-Roqeuplo A.P. Phaeochromocytomas and secreting paragangliomas. Orphanet J Rare Dis 2006, 49:1750-1772.
10. Gangopadhyay K., Basker V., Toogood A. A case of exclusive dopamine-secreting paraganglioma. Clin Endocrinol 2007, 68:491-497.
11. Eisenhofer G., Goldstein D., Sullivan P., et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005, 90:2068-2075.
12. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 2003, 60:21-32.
13. de la Mora M.P., Gallegos-Cari A., Arizmendi-García Y., et al. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: structural and functional analysis. Prog Neurobiol 2010, 90:198-216.
14. Guillin O., Abi-dargham A., Laurelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 2007, 78:1-39.
15. Fitzgerald P.J. Black bile: are elevated monoamines an etiological factor in some cases of major depression?. Med Hypotheses 2013, 80:823-826.
16. Howes O., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009, 35:549-562.
17. Javit D. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 2010, 47:4-16.
18. Baker G., Hallak J., Dilullo A., et al. Amino acids in schizophrenia - glycine, serine and arginine. Handbook of schizophrenia spectrum disorders 2011, 253-262. Springer, Dordrecht. M. Ritsner (Ed.).
19. Bray N., Leweke M., Kapur S., et al. The neurobiology of schizophrenia: new leads and avenues for treatment. Curr Opin Neurobiol 2010, 28:810-815.
20. Cantor-Graae E. The contribution of social factors to the development of schizophrenia: a review of recent findings. Can J Psychiatry 2007, 52:277-286.
21. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev 1997, 104:667.